Product Description: Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9(1):e49. /[2]Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81.